RDNT:NSD-RadNet Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 82.56

Change

-1.03 (-1.23)%

Market Cap

USD 5.00B

Volume

0.51M

Analyst Target

USD 21.67
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.71 (+0.87%)

USD 34.17B
ILMN Illumina Inc

-1.45 (-0.98%)

USD 23.86B
ICLR ICON PLC

-8.37 (-3.94%)

USD 18.82B
NTRA Natera Inc

+25.85 (+19.13%)

USD 15.36B
EXAS EXACT Sciences Corporation

+0.57 (+1.14%)

USD 13.02B
MEDP Medpace Holdings Inc

+1.13 (+0.31%)

USD 9.93B
SHC Sotera Health Co

-0.22 (-1.42%)

USD 4.49B
GH Guardant Health Inc

+1.88 (+6.32%)

USD 3.53B
NEOG Neogen Corporation

-0.16 (-1.04%)

USD 3.13B
TWST Twist Bioscience Corp

-2.77 (-6.12%)

USD 2.66B

ETFs Containing RDNT

XHS SPDR® S&P Health Care Se.. 2.06 % 0.35 %

-1.07 (-1.10%)

USD 0.08B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.51 (-1.10%)

USD 0.18B
WMCR 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 137.45% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 137.45% 96% N/A 96% N/A
Trailing 12 Months  
Capital Gain 155.13% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 155.13% 92% A 95% A
Trailing 5 Years  
Capital Gain 358.92% 97% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 358.92% 97% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 51.22% 80% B- 87% B+
Dividend Return 51.22% 80% B- 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 77.06% 40% F 26% F
Risk Adjusted Return 66.46% 96% N/A 87% B+
Market Capitalization 5.00B 86% B+ 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector